Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms
Endocrine-Related Cancer · 22.01.2024 · 31 (4)
DOI: 10.1530/erc-23-0292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, erschienen am 22.01.2024. Verfasst von Darren Cowzer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Cell-Free Nucleic Acids, Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma–tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well-differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%), and ATRX (12%). Twenty-three out of 25 (92%) patients underwent tumor tissue NGS. Tissue–plasma concordance for select genes was as follows: DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially actionable alterations were identified in cfDNA of 8 patients, including TSC2 (4; level 3b), ATM (1; level 3b), ARID1A (2; level 4), and KRAS (1; level 4). An ETV6 : NTRK fusion detected in tumor tissue was treated with larotrectinib; at progression, sequencing of cfDNA identified an NTRK3 G623R alteration as the acquired mechanism of resistance; the patient enrolled in a clinical trial of a second-generation TRK inhibitor with clinical benefit. In metastatic PanNENs, cfDNA-based NGS identified tumor-associated mutations in 66% of plasma samples with a high level of plasma-tissue agreement in PanNEN-associated genes. Clonal evolution, actionable alterations, and resistance mechanisms were detected through circulating cfDNA genotyping.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Pathology and laboratory medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Weill Medical College of Cornell University, New York, New York, USA.
ORCID-Profile: Darren Cowzer, Nitya Raj
Zitieren
APA
Cowzer, D., Shah, R. H., Chou, J. F., Kundra, R., Punn, S., Fiedler, L., DeMore, A., Capanu, M., Berger, M. F., Reidy-Lagunes, D., & Raj, N. (2024). Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer, 31(4). https://doi.org/10.1530/erc-23-0292
Vancouver
Cowzer D, Shah RH, Chou JF, Kundra R, Punn S, Fiedler L, et al. Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms. Endocrine-Related Cancer. 2024;31(4). doi:10.1530/erc-23-0292
BibTeX
@article{Cowzer2024,
author = {Cowzer, Darren and Shah, Ronak H and Chou, Joanne F and Kundra, Ritika and Punn, Sippy and Fiedler, Laura and DeMore, April and Capanu, Marinela and Berger, Michael F and Reidy-Lagunes, Diane and Raj, Nitya},
title = {Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms},
journal = {Endocrine-Related Cancer},
year = {2024},
volume = {31},
number = {4},
doi = {10.1530/erc-23-0292}
}
EUVIMED